Medium Biosciences

Medium Biosciences is a private, pre-clinical stage biotech founded in 2019 and based in San Diego, California. The company operates at the intersection of AI/ML and biologics, building a proprietary platform for the computational design and engineering of novel proteins intended for cell therapies and regenerative medicine. As a platform-focused therapeutics company, it is likely in a pre-revenue, R&D-intensive phase, backed by undisclosed investors, and aiming to translate its AI-driven designs into viable therapeutic programs.

AI and machine learning platform for de novo protein design and end-to-end protein engineering, focused on creating novel biologics for cell therapy and tissue engineering applications.

Medium Biosciences competes in the crowded and rapidly evolving AI drug discovery space against companies like Generate Biomedicines, Absci, and Recursion, as well as more established regenerative medicine and protein engineering firms. Its differentiation hinges on the specific capabilities of its de novo design platform and its focused application to cell therapy challenges.